ARTISTRY-7
14 Sep 2023
ARTISTRY-7
NCT05092360
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Alkermes, Inc.
Cancer Type | Female reproductive system |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Female |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2022-01-10 |
Anticipated End Date | 2026-12-01 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead/Kate Penta |
admin@cancerresearchsa.com.au | |
Phone | 08 8359 2565 |
Principal Investigator | Meena Okera |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs